Microglia – why we need embryonic stem cells research…

I am hereby posting a link to a very interesting article published on Medical News Today on October 25th 2010..

I believe it to be interesting as this particular research may pave a way for being able to prevent MS before we’re even born….

http://www.medicalnewstoday.com/articles/205648.php

Hopefully you’ll find it as interesting as I have : )

Cheers!

Advertisements

Ocrelizumab – reduces MS disease activity

As taken from the Medical News Today (Oct. 20.2010) website:

Ocrelizumab is an investigational humanized monoclonal antibody designed to selectively target CD20-positive B-cells, which are believed to play a critical role in multiple sclerosis (MS). It then interacts with the body’s immune system to eliminate CD20-positive B-cells.

Simply put, Ocrelizumab has demonstrated, through trials (they refer to phase II in particular), that there is a significant reduction in disease activity in patients with MS…as measured by brain lesions and relapse rate.

In fact, the reductions were impressive: the total reductions in the number of brain lesions detected by MRI scanning was 96% for 2000mg Ocrelizumab and 89% for 600mg Ocrelizumab (compared to placebo). Disease activity was also reduced significantly…

For more info on Ocrelizumab please visit the Medical News Today link (you can find under “links”).

Disease activity was also measured by reduction in annualized relapse rate (ARR), the rate of attacks or flare-ups per patient-year. At week 24, ARR was significantly lowered versus placebo with a reduction of 73% for ocrelizumab 2000mg and 80% for ocrelizumab 600mgii.